Welcome to the Newsroom
12 January 2017
Prima BioMed Commences Recruitment for Second Cohort of Melanoma Trial
SYDNEY, AUSTRALIA - Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD) (“Prima” or the “Company”) today announced that the first patient has been dosed for the second cohort of its clinical trial program for IMP321 in combination with KEYTRUDA® being conducted in Australia. The second cohort will recruit up to six patients with unresectable or metastatic melanoma that have had a suboptimal response to KEYTRUDA.
Article as pdf